サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362911

抗感染症薬の市場規模、シェア、動向分析レポート：タイプ/薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2030年

Anti-infective Agents Market Size, Share & Trends Analysis Report By Type/Drug Class (Antivirals, Antifungals), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗感染症薬の市場規模、シェア、動向分析レポート：タイプ/薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月06日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗感染症薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗感染症薬市場規模は、2023年から2030年にかけて1.2％のCAGRで成長し、2030年までに1,506億米ドルに達すると予測されています。

HIV、H1N1、エボラウイルスなどの感染症の流行増加は、ここ数十年の地域社会の行動パターンの大きな変化を反映しています。社会の変化とヘルスケア専門家や患者の意識の高まりが成長を促進しています。

世界保健機関（WHO）や疾病対策予防センター（CDC）などの組織は、感染症がもたらす致命的な影響や早期治療の重要性に関する人々の意識を広めることに積極的に取り組んでいます。CDCは、ブラジル、中国、ナイジェリア、インドなどの発展途上国において、国民保健省（NHM）と協力し、感染症に対する認識を広め、治療を強化しようとしています。

しかし、効力と有効性を高めた新規治療薬のイントロダクションや、市中獲得細菌性肺炎（CABP）の治療薬として2018年にオマダサイクリンが商業化されるなど、パイプライン製品の商業化が、抗感染症薬市場の成長を促進すると予想されます。

抗感染症薬市場レポートハイライト

  • 抗ウイルス剤は、HIV治療薬ビクリビロクのような新しい強力な抗ウイルス剤に関連する高価格のため、2022年の市場シェアは53.2%で最大セグメントと推定されます。
  • 抗菌薬セグメントは、予測期間中に最も速いCAGR 4.2%を記録すると予想されます。抗菌薬は市販されているため、処方が増え、入手しやすくなっており、この分野をさらに牽引すると予想されます。
  • 重篤で生命を脅かす感染症の治療と予防のための併用薬の開発は、抗感染症薬の使用を促進すると予想されます。例えば、2012年にギリアド・サイエンシズ社は、レトロウイルス治療歴のないHIV患者の治療に使用される4剤（コビシスタット、エルビテグラビル、エムトリシタビン、テノホビルジソプロキシルフマル酸塩）を含む包括的治療レジメンであるストリビルドを発売しました。
  • 経口投与経路は、新製品開発と強力な製品パイプラインの存在により、2022年には最大のセグメントになると推定されます。
  • 病院薬局は2022年に28.8％の最高収益シェアで市場を独占し、eコマースは予測期間中に最も急成長するセグメントと予測されます。
  • 北米は2022年に世界の業界を支配し、全体の収益の37.0%で最大のシェアを占めました。小児と成人の両方における院内感染を含む感染症の高い流行と、その結果としての抗生物質の過剰使用と、処方箋以外の抗感染薬へのアクセスの増加が主な促進要因です。
  • アジア太平洋地域は、新薬に対するアンメット・メット・ニーズが高いこと、ヘルスケア・インフラが急速に整備され、医療従事者や患者の意識が高まっていることから、急成長している地域セグメントの一つです。
  • 効果的な疾病管理には、新製品開発、M&A、共同開発、事業拡大など、さまざまな長期戦略が必要です。例えば、2015年、ReViral社はウェルカム・トラストからRV521の開発に2,100万米ドルの資金提供を受けた。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗感染症薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 抗感染症薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗感染症薬：タイプ/薬剤クラスの推定・動向分析

  • 抗感染症薬市場：重要なポイント
  • 抗感染症薬市場：動向と市場シェア分析、2022年および2030年
  • 抗菌剤
    • 抗菌剤市場推計・予測、2018年から2030年まで
    • 抗菌剤クラスの市場推計・予測、2018年から2030年まで
  • 抗ウイルス薬
    • 抗ウイルス薬市場推計・予測、2018年から2030年まで
  • 抗真菌薬
    • 抗真菌薬市場推計・予測、2018年から2030年まで
    • 抗真菌薬クラスの市場推計・予測、2018年から2030年まで

第5章 抗感染症薬市場：投与経路の推定・動向分析

  • 抗感染症薬市場：重要なポイント
  • 抗感染症薬市場：動向と市場シェア分析、2022年および2030年
  • 局所
  • 経口
  • Ⅳ
  • その他

第6章 抗感染症薬市場：流通チャネルの推定・動向分析

  • 抗感染症薬市場：重要なポイント
  • 抗感染症薬市場：動向と市場シェア分析、2022年および2030年
  • 病院薬局
  • 小売薬局
  • 専門薬局
  • eコマース
  • その他

第7章 抗感染症薬市場：地域推定・動向分析

  • 地域別の見通し
  • 地域別の抗感染症薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Pfizer Inc.
    • Abbott.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Sandoz International GmbH
    • B. Braun SE
    • Xellia Pharmaceuticals
    • Mankind Pharma
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 3 North America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 4 North America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 6 U.S. anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 7 U.S. anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 9 Canada anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 12 Europe anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 13 Europe anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 16 Germany anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Germany anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 18 Germany anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 19 UK anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 20 UK anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 21 UK anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 22 France anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 23 France anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 24 France anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 25 Italy anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Italy anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 27 Italy anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 28 Spain anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 29 Spain anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 30 Spain anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 33 Sweden anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 34 Norway anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Norway anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 36 Norway anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 37 Denmark anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Denmark anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 39 Denmark anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Japan anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 45 Japan anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 46 Japan anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 47 China anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 48 China anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 49 China anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 50 India anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 51 India anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 52 India anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 53 Australia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Australia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 55 Australia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 56 Thailand anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 57 Thailand anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 58 Thailand anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 59 South Korea anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 60 South Korea anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 61 South Korea anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 62 Latin America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Latin America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 64 Latin America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 65 Latin America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 66 Brazil anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 67 Brazil anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Brazil anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 69 Mexico anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 70 Mexico anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Mexico anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 72 Argentina anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Argentina anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 Argentina anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 75 Middle East and Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Middle East and Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 77 Middle East and Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 78 Middle East and Africa anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 79 South Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 80 South Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 South Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 Saudi Arabia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 85 UAE anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 86 UAE anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 UAE anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 90 Kuwait anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Anti-infective agents: Market outlook
  • Fig. 9 Anti-infective agents: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Anti-infective agents market driver impact
  • Fig. 15 Anti-infective agents market restraint impact
  • Fig. 16 Anti-infective agents market strategic Initiatives analysis
  • Fig. 17 Anti-infective agents market: Type movement analysis
  • Fig. 18 Anti-infective agents market: Type outlook and key takeaways
  • Fig. 19 Antibacterials market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Antibacterials drug class market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Antivirals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Antifungals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Anti-infective agents market: Route of administration movement analysis
  • Fig. 36 Anti-infective agents market: Route of administration outlook and key takeaways
  • Fig. 37 Topical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Oral market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 IV market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Anti-infective agents market: Distribution channel movement analysis
  • Fig. 42 Anti-infective agents market: Distribution channel outlook and key takeaways
  • Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Specialty pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 E-commerce market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Global anti-infective agents market: Regional movement analysis
  • Fig. 49 Global anti-infective agents market: Regional outlook and key takeaways
  • Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Europe. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 72 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 73 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 75 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)
目次
Product Code: 978-1-68038-973-9

Anti-infective Agents Market Growth & Trends:

The global anti-infective agents market size is expected to reach USD 150.6 billion by 2030, registering a CAGR of 1.2% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Anti-infective Agents Market Report Highlights:

  • Antiviral was estimated to be the largest segment with a market share of 53.2% in 2022 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
  • Antibacterial segment is anticipated to register the fastest CAGR of 4.2% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
  • Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
  • Oral route of administration was estimated to be the held largest segment in 2022 owing to new product development and presence of strong product pipeline
  • Hospital pharmacy dominated the market with the highest revenue share of 28.8% in 2022 while e-commerce is expected to be the fastest-growing segment during the forecast period
  • North America dominated the global industry in 2022 and accounted for the largest share of 37.0% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
  • Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
  • Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Route of Administration
    • 1.1.3. Distribution Channel
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary route of administrations
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Infective Agents Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Anti-Infective Agents Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Anti-Infective Agents: Type/Drug Class Estimates & Trend Analysis

  • 4.1. Anti-Infective Agents Market: Key Takeaways
  • 4.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Antibacterials
    • 4.3.1. Antibacterials market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Antibacterials drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.1. Cephalosporins
      • 4.3.2.1.1 Cephalosporins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.2. Penicillin
      • 4.3.2.2.1 Penicillin market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3. Fluoroquinolones
      • 4.3.2.2.2 Fluoroquinolones market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3 Macrolides
      • 4.3.2.3.1 Macrolides market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.4 Carbapenem
      • 4.3.2.4.1 Carbapenem market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.5 Others
      • 4.3.2.5.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Antivirals
    • 4.4.1. Antivirals market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.5. Antifungals
    • 4.5.1. Antifungals market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.5.2. Antifungals drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.1. Azoles
      • 4.5.2.1.2 Azoles market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.2. Echinocandins
      • 4.5.2.2.3 Echinocandins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3. Polyenes
      • 4.5.2.2.4 Polyenes market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3 Others
      • 4.5.2.3.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Anti-Infective Agents Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Anti-Infective Agents Market: Key Takeaways
  • 5.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. IV
    • 5.5.1. IV market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Anti-Infective Agents Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Anti-Infective Agents Market: Key Takeaways
  • 6.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.6. E-Commerce
    • 6.6.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Other market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Anti-Infective Agents Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Anti-Infective Agents Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Pfizer Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Abbott.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Gilead Sciences, Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bristol-Myers Squibb Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck & Co., Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Sandoz International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. B. Braun SE
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Xellia Pharmaceuticals
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Mankind Pharma
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Bayer AG
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. AstraZeneca
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Boehringer Ingelheim International GmbH.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives